SCHEMBL7625869

SCHEMBL7625869

Cc1ccc(CNCc2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.62
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
TDP1 Q9NUW8 1/20 0.58
CHRM2 P08172 1/20 0.57
TP53 P04637 1/20 0.55
THRB P10828 1/20 0.55
BCHE P06276 1/20 0.53
ATM Q13315 2/20 0.53
CA12 O43570 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CA9 Q16790 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MAOA P21397 1/20 0.52
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17447224 0.94 HTT (0.57) HTTSMN1; SMN2MEN1KMT2ATDP1
SCHEMBL9973111 0.91 MEN1 (0.74) HTTSMN1; SMN2MEN1KMT2ATDP1
SCHEMBL842161 0.90 CHRM2 (0.67) HTTSMN1; SMN2MEN1KMT2ATDP1
SCHEMBL10054993 0.87 MEN1 (0.74) MEN1KMT2ATDP1CHRM2THRB
SCHEMBL4497825 0.87 HTT (0.55) HTTSMN1; SMN2MEN1KMT2ATDP1
SCHEMBL19245652 0.86 GAA (0.74) HTTSMN1; SMN2MEN1KMT2ATDP1
SCHEMBL1654 0.84 MEN1 (0.78) MEN1KMT2ATDP1CHRM2THRB
SCHEMBL5799878 0.84 MEN1 (0.78) MEN1KMT2ATDP1CHRM2THRB
Benzene SCHEMBL11697595 0.84 MEN1 (0.78) MEN1KMT2ATDP1CHRM2THRB
Toluene SCHEMBL16880241 0.84 MEN1 (0.77) HTTSMN1; SMN2MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119350180-A Industrial preparation method and application of high-purity alpha-aminonitrile 哈尔滨理工大学 2025-01-24 CN claimed
WO-2013105100-A1 PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF SYMED LABS LIMITED (IN) 2013-07-18 WO claimed
CN-122028918-A TRIM7 inhibitors and uses thereof 沙塔克实验室有限公司 2026-05-12 CN disclosed
WO-2025042798-A1 TRIM7 INHIBITORS AND USES THEREOF SHATTUCK LABS, INC. (US) 2025-02-27 WO disclosed
CN-119350180-A Industrial preparation method and application of high-purity alpha-aminonitrile 哈尔滨理工大学 2025-01-24 CN disclosed
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF THE BROAD INSTITUTE, INC. 2023-06-22 US disclosed
CN-115697415-A Techniques for preventing or treating infections 拜尔哈文制药股份有限公司 2023-02-03 CN disclosed
EP-3288948-B1 FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS NOVARTIS AG (CH) 2019-11-20 EP disclosed
US-20170191976-A1 Method and Kit for Detecting Lead in a Solid Sample THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-07-06 US disclosed
WO-2013105100-A1 PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF SYMED LABS LIMITED (IN) 2013-07-18 WO disclosed
US-20080033171-A1 Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-02-07 US disclosed
WO-2005087726-A1 NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-22 WO disclosed
US-6444407-B1 Plate for liquid crystal display, method and polymeric compositions INTERNATIONAL BUSINESS MACHINES CORPORATION 2002-09-03 US disclosed
US-5527955-A AGONIST OF GAMMA AMINOBUTYRIC ACID JOHN WYETH & BROTHER, LIMITED (GB) 1996-06-18 US disclosed
EP-0345068-B1 Agonist of gamma-aminobutyric acid WYETH JOHN & BROTHER LTD (GB) 1995-03-15 EP disclosed
US-5321047-A Antidepressant JOHN WYETH & BROTHER, LIMITED (GB) 1994-06-14 US disclosed
EP-0345068-A2 Agonist of gamma-aminobutyric acid JOHN WYETH & BROTHER LIMITED (GB) 1989-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033171-A1 Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon THEM6, SOD1, SLC30A6 HTT 3376/4885SMN1; SMN2 4366/4885MEN1 1595/4885
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF ERBB2, ACP1, TK1 HTT 4428/4885SMN1; SMN2 3469/4885MEN1 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.